E7107
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout E7107
E7107 is a phase 1 stage product being developed by Eisai for Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT00499499. Target conditions include Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00499499 | Phase 1 | Active |
| NCT00459823 | Phase 1 | Active |
Competing Products
20 competing products in Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mFOLFOX regimen + Mitazalimab | Alligator Bioscience AB | Phase 2/3 | 35 |
| Intratumoral Mitazalimab + Intratumoral Nivolumab | Alligator Bioscience AB | Phase 1 | 26 |
| mRNA-2416 | Moderna | Phase 2 | 0 |
| Doxorubicin Hydrochloride Liposome Injection | Dr. Reddy's Laboratories | Phase 1 | 26 |
| E7389 | Eisai | Phase 1 | 29 |
| Veliparib | AbbVie | Phase 2 | 27 |
| AK-105 | Akeso | Phase 1 | 29 |
| XL820 | Exelixis | Phase 1 | 26 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 30 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 29 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 31 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 30 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 35 |
| pemetrexed | Eli Lilly | Phase 2 | 27 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 29 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 18 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 35 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 35 |